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Abstract
Purpose: Huntington’s disease is a rare condition. Patients are commonly treated with antipsychotics and tetrabenazine. The
evidence of their effect on disease progression is limited and no comparative study between these drugs has been
conducted. We therefore compared the effectiveness of antipsychotics on disease progression.
Methods: 956 patients from the Huntington French Speaking Group were followed for up to 8 years between 2002 and
2010. The effectiveness of treatments was assessed using Unified Huntington’s Disease Rating Scale (UHDRS) scores and
then compared using a mixed model adjusted on a multiple propensity score.
Results: 63% of patients were treated with antipsychotics during the survey period. The most commonly prescribed
medications were dibenzodiazepines (38%), risperidone (13%), tetrabenazine (12%) and benzamides (12%). There was no
difference between treatments on the motor and behavioural declines observed, after taking the patient profiles at the start
of the drug prescription into account. In contrast, the functional decline was lower in the dibenzodiazepine group than the
other antipsychotic groups (Total Functional Capacity: 0.4160.17 units per year vs. risperidone and 0.5460.19 vs.
tetrabenazine, both p,0.05). Benzamides were less effective than other antipsychotics on cognitive evolution (Stroop
interference, Stroop color and Literal fluency: p,0.05).
Conclusions: Antipsychotics are widely used to treat patients with Huntington’s disease. Although differences in motor or
behavioural profiles between patients according to the antipsychotics used were small, there were differences in drug
effectiveness on the evolution of functional and cognitive scores.
Citation: De´same´ricq G, Dolbeau G, Verny C, Charles P, Durr A, et al. (2014) Effectiveness of Anti-Psychotics and Related Drugs in the Huntington French-
Speaking Group Cohort. PLoS ONE 9(1): e85430. doi:10.1371/journal.pone.0085430
Editor: Josef Priller, Charite´-Universita¨tsmedizin Berlin, Germany
Received February 27, 2013; Accepted December 5, 2013; Published January 15, 2014
Copyright:  2014 De´same´ricq et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by cooperative contracts between the Institut National de la Sante´ et la recherche Medicale (INSERM), the Association´
Franc¸aise contre les Myopathies (AFM), the Association Huntington France (AHF), and the Groupement d’Intereˆt Scientifique (GIS) - Institut des Maladies Rares et
l’AP-HP (DRCD). The team received a grant (about 5000 euro) from EUSA Pharma but EUSA Pharma did not fund directly this study. They wish only data on the use
of tetrabenazine, not any result about effectiveness and comparisons. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: PM has received grant/research support from EUSA Pharma. This does not alter the authors’ adherence to all the PLOS ONE policies on
sharing data and materials.
* E-mail: patrick.maison@hmn.aphp.fr
. These authors contributed equally to this work.
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e85430
Introduction
Drug prescription is a complex process that takes into account
many factors: primary clinical data, patient preferences, the
prescriber’s clinical and personal experience, external rules and
constraints and scientific evidence [1]. Randomised controlled
trials (RCTs) are considered the best practice methodology (the
gold standard) to provide evidence about drug efficacy. However,
RCTs have important limitations for informing clinical practice
and policy decisions about treatments. In particular, it is unclear
whether findings can be applied to patients seen in routine practice
and RCTs do not make comparisons between several prescription
options. Recent statistical tools [2] can now help address these
issues by allowing multiple comparisons through cohort studies in
‘‘real-world’’ conditions. Such comparisons are particularly useful
when studying rare diseases, as the number of patients can be low
and may limit the feasibility of clinical trials.
Huntington’s disease (HD) is a rare, autosomal dominant,
neurodegenerative disorder resulting from expansion of a CAG
repeat within the IT15 huntingtin (HTT) gene on chromosome 4p
[3]. It is characterised by choreiform movements and progressive
dementia, and, in 33% to 76% of cases, psychiatric manifestations
(for example depression, apathy or irritability)[4]. Recent reviews
of available drug trials and case reports [5–7] conclude that the
management of HD is poorly documented. Antipsychotics and
related drugs (for example tetrabenazine) are most commonly used
for the treatment of chorea [8]. The use of antipsychotics and
related drugs (APRs) differs between countries: olanzapine is
widely prescribed in France and in the United-Kingdom, tiapride
in Germany, and haloperidol is more common in Italy [9]. In
France, only tetrabenazine and tiapride are approved for chorea.
Little is known about the differences between the effects of
different antipsychotics on motor abilities, cognitive disorders,
psychiatric disturbances or metabolic impairments.
We aimed to describe APR use in HD patients in conditions of
routine practice and compare their effectiveness using disease
progression scores.
Materials and Methods
The study, carried out between 2002 and 2010, was based on
the cohort from the Huntington French Speaking Network
(HFSG, http://www.hdnetwork.org).
Patients
Patients were recruited at 13 centres in France and Belgium
(Angers, Bordeaux, Bruxelles, Caen, Creteil, Lille, Lyon, Mar-
seille, Nantes, Paris, Rennes, Strasbourg, and Toulouse); 956
patients, all genetically confirmed (CAG $37 repeats), completed
at least one Unified Huntington’s Disease Rating Scale (UHDRS)
assessment. Patients were followed for up to 8 years between 2002
and 2010; the mean follow-up was 28.2 months (Table 1). For
more than half of the patients, motor symptoms were the initial
symptom of the disease. At the time of their first admission in the
Huntington French-Speaking Network, 408 of the HD patients
(44%) were in Stage 1, 276 (30%) were in Stage 2, 182 (19%) were
in Stage 3, 53 (6%) were in Stage 4, and 12 (1%) were in Stage 5
(the final stage) of the disease as characterised by their Total
Functional Capacity (TFC) [10].
Assessments
Patient demographics, age at onset of HD, expanded CAG
repeat and body mass index were recorded. The motor, cognitive,
behavioural and functional capabilities of each patient were
assessed annually using the UHDRS [11]. The motor score
quantified 15 different motor signs, with higher scores indicating
more severely impaired motor function. The cognitive assessment
was composed of three standardised tests: the Stroop interference
test, Symbol Digit Modalities Test (SDMT), and the verbal fluency
test. The behaviour score measured 11 characteristics; the
frequency and severity of each of these were multiplied to give a
single score for each characteristic and then added together to give
the total behaviour score. The functional assessment tested
common daily tasks using three measures: the Total Functional
Capacity (TFC), the Independence Scale and the Functional
Assessment Scale. All medications and indications for their use
were recorded each time the patient was assessed, as well as the
time since last evaluation. The average time between first visit and
prescription of a drug was 13 months. We focused on antipsy-
chotics (N05A) and the related drug tetrabenazine (N07XX06) as
classified according to the Anatomical Therapeutic Chemical
(ATC) Classification System [12]. These were chosen as they were
the most commonly prescribed APRs within the cohort. The
period of exposure to a drug was defined as the time between the
date of prescription and the acknowledged end of prescription. All
data were collected from electronic case report forms.
Statistical methods
Descriptive statistics are presented as means and standard
deviation (for quantitative variables) or frequency counts by
category (for qualitative variables).
We describe the baseline characteristics of the patient at the
time of the first prescription of the drug. These were compared by
univariate analysis using Chi2 tests or Fisher’s exact tests (for
qualitative variables) and Kruskal-Wallis tests (for quantitative
variables). If a patient received more than one drug at the same
time or during follow-up, each period of drug prescription was
taken into account independently.
We used a mixed model, adjusted with a multiple propensity
score, to compare the effects of treatments on UHDRS scores
[13]. Mixed models allow data from subjects tested once and data
from those who participated in multiple evaluations to be
evaluated together. Thus, any bias due to missing data, although
not completely eliminated, is minimized. Multiple propensity
scores take into account the lack of randomisation; this lack of
randomisation is inherent in the observational data due to
differences in treatment assignment by physicians and the
conditional probability of being treated based on patient profile
at the time of the first prescription. Firstly, multiple propensity
scores were estimated for each subject and each drug using a
multinomial regression model. Baseline characteristics were
included if they had an independent association with the
prescription of a drug (P,0.25). The size of centre (either fewer
or more than 100 participants) was also included. Secondly, we
estimated causal effects. These included: fixed effects of treatment
levels, time from the start of the treatment until the next UHDRS
score was taken, the treatment x time interaction and propensity
score, and a random effect for the subject/treatment-specific
intercepts. We calculated the overall change in UHDRS score
over time and compared the effectiveness of treatments.
Analyses were performed using SAS 9.00 (SAS Institute Inc,
Cary, North Carolina). All P values were two-tailed, and statistical
significance was defined as P,0.05 for all tests.
Ethics statement
All patients, whose data are included in the database of the
Huntington French-speaking Group cohort, carefully read an
information sheet that present the goal of the network and provide
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their verbal consent to participate the day at the first evaluation. In
France, as the study was observational and no biological sample
was collected, the data do not justify specific patient consent. The
study was approved by the local ethics committee (Comite´ de
Protection des Personnes Ile-de-France IX, Cre´teil, France).
Results
Prescription of APRs
During the study period, 602 patients (63% of the overall HD
population) received APRs. The most commonly prescribed
medications were dibenzodiazepines (38%, mainly olanzapine),
risperidone (13%), tetrabenazine (12%) and benzamides (12%,
mainly tiapride). Sixty-four percent of these patients were using
APRs because of chorea and the others for behavioural disorders
such as irritability, aggressiveness or agitation. Figure 1 shows the
percentage of prescriptions for each class of drug between 2002
and 2010. As only a small number of patients were treated with
aripiprazole, this medication was not taken into account in the
following analyses.
Characteristics of the treated population at the first
prescription
A total of 347 patients treated with APRs were evaluated just
before the beginning of their treatment. Patients treated with
dibenzodiazepines had a shorter history of HD at baseline whereas
neither age nor age at disease onset differed between patients
treated with the other APRs (Table 2). Approximately half of all
patients were also treated with an antidepressant. At the initiation
of APR treatment, patients taking dibenzodiazepines tended to
have less severe motor impairments than those taking other
treatment (P=0.05); there was no significant difference in motor
score, except in eye movement scores for which P=0.006.
Behavioural scores were similar between APR groups. Scores on
the Functional Assessment Scale (FAS), Independence Scale (IS)
and Total Functional Capacity (TFC) differed between the four
treatment groups. Patients taking dibenzodiazepines were less
disabled than others; they had lower FAS scores (32.466.3) and
the highest IS (75.7617.2) and TFC (7.863.4) scores. The four
APR treatment groups performed differently in the verbal fluency
test (p,0.05) and the Stroop interference test (p,0.05). Dibenzo-
diazepines were prescribed to patients with less impairment as
defined by these tests.
Impact of these APRs on disease evolution
No significant differences were observed between treatments in
terms of motor or behavioural scores (table 3). There was no
significant difference between treatment groups for changes in
score for chorea (dibenzodiazepines: 0.360.2 units per year,
risperidone: 0.460.4 units per year, tetrabenazine: 0.860.5 units
per year, benzamides: 0.260.5 units per year), and for dystonia
impairment (dibenzodiazepines: 0.860.1 units per year, risperi-
done: 0.960.3 units per year, tetrabenazine: 1.060.4 units per
year, benzamides: 1.160.3 units per year) but for total motor score
minus involuntary movement scores, dibenzodiazepines and
risperidone performed better than tetrabenazine (dibenzodiaze-
pines: 2.260.2 units per year, risperidone: 2.460.4 units per year,
tetrabenazine: 4.060.6 units per year, benzamides: 3.360.5 units
per year). There was no significant difference between treatment
groups for changes in score for apathy (dibenzodiazepines:
0.460.2 units per year, risperidone: 0.560.3 units per year,
tetrabenazine: 1.060.4 units per year, benzamides: 0.460.4 units
per year), obsessive-compulsive symptoms (dibenzodiazepines:
0.660.2 units per year, risperidone: 0.660.5 units per year,
tetrabenazine: 0.060.6 units per year, benzamides: 0.060.6 units
per year), symptoms of depression (dibenzodiazepines: 20.760.4
units per year, risperidone: 20.760.8 units per year, tetrabena-
zine: 20.760.9 units per year, benzamides: 20.560.9 units per
year) or psychosis (dibenzodiazepines: 0.060.1 units per year,
risperidone: 0.060.1 units per year, tetrabenazine: 0.160.1 units
per year, benzamides: 0.060.1 units per year). For irritability and
aggression, dibenzodiazepines and tetrabenazine performed better
than risperidone (dibenzodiazepines: 20.560.2 units per year,
risperidone: 0.660.4 units per year, tetrabenazine: 20.960.5
units per year, benzamides: 20.660.5 units per year). An
adjustment on multiple propensity score and antidepressant use
over time did not modify the results for behavioral scores.
Figure 1. Percentage of prescriptions made for each class of antipsychotic and related drugs (2002–2010). Aripiprazole and
tetrabenazine obtained market authorisation in 2004 and 2005, respectively.
doi:10.1371/journal.pone.0085430.g001
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There were, however, significant differences for functional
impairment: patients taking dibenzodiazepine showed a greater
change in TFC score than patients receiving risperidone or
tetrabenazine (p,0.05).
Overall, cognitive abilities decreased to a greater extent with
benzamide treatment than with dibenzodiazepine, risperidone or
tetrabenazine treatments (p,0.05). The impairment in cognition
was greater with benzamides than with dibenzodiazepines as
assessed with the symbol digit modality test, Stroop colour and
interference measures (p,0.05). Significant differences in the
literacy fluency (1 minute timing), Stroop colour and interference
measures were observed between the benzamide group and the
tetrabenazine group (p,0.05). Performance in the symbol digit
modality test was also significantly poorer in the benzamide group
of patients than in the risperidone group (p,0.05).
The change in body mass index (BMI) over time depended on
the APR used. BMI change was significantly less with benzamides
(20.960.3 kg/m2 per year) than with dibenzodiazepines
(0.260.1 kg/m2 per year) or risperidone (0.060.2 kg/m2 per
year).
There was no significant difference between treatments when
analysing tiapride as single drug (n= 43 out of 56 benzamide),
except for the results of some of the functional and cognitive
assessments. Deterioration was less marked in the Functional
Assessment Scale for patients on dibenzodiazepines than for those
on tiapride (p,0.05) as well as in the Total Functional Capacity in
patients on dibenzodiazepines comparing with patients on tiapride
(p,0.05). Decline in the Stroop interference score was greater in
patients on tiapride than those on dibenzodiazepines or tetraben-
azine (p,0.05).
Changes in control and treatment groups
In a set of secondary analyses, the group, who had never
received an APR, was less severely affected than the groups
administered antipsychotics, and the propensity scores failed to
correct the differences observed at baseline for motor impairments,
some of the behavioural items (dystonia, apathy, obsessive-
compulsive symptoms and psychosis), the functional assessment
scale and the total functional capacity, and some cognitive
assessments (literacy fluency and symbol digit modality test). For
chorea, behaviour and symptoms of depression, the patterns of
changes through time did not differ between the groups.
Irritability and aggression progressed faster in the risperidone
group than in the controls (0.860.4 units per year, p,0.05). There
were significant differences for the independence scale: deteriora-
tion was less marked for controls than patients. Decline was
greater in the benzamide than controls groups at all Stroop scores
(p,0.05) and also at Stroop word and interference (p,0.05) in the
dibenzodiazepine group. There were significant differences in the
changes in BMI between the control group (20.160.1 kg/m2 per
year) and the dibenzodiazepine group, where the BMI increased,
and benzamide group, where the BMI decreased.
Discussion
We followed 956 patients from 2002 to 2010; of these, 63%
were treated with antipsychotics and related drugs (APRs).
Dibenzodiazepines were given to patients with relatively less
disability on functional and cognitive scales (literal fluency and
Stroop interference) at the time of the first prescription. Patient
profiles did not differ in other UHDRS components. Taking into
account existing differences in patient profiles at the beginning of
Table 2. Baseline patient profile on the day of first prescription of an anti-psychotic or related drug.
Dibenzodiazepines Risperidone Tetrabenazine Benzamides p
Age (year) 187 49.6611.6 60 52.1610.1 63 53.1612.4 56 49.7610.5 NS
Age at HD onset (year) 179 42.9612.0 55 44.0610.1 61 44.9612.3 52 42.0610.4 NS
Males (%) 186 52.2 60 48.3 63 49.2 56 60.7 NS
Study year 175 11.663.4 54 10.863.2 58 11.663.3 54 11.963.4 NS
Duration of HD (year) 179 6.965.5 55 8.565.0 61 8.564.7 52 8.064.6 0.002
CAG repeat length 187 45.364.1 60 44.063.4 63 44.563.3 56 45.664.2 0.05
Antidepressant use (%) 187 49.2 60 53.3 63 65.1 56 44.6 NS
BMI 153 22.863.7 51 23.264.5 44 22.263.5 45 23.263.7 NS
Motor score 177 44.3621.7 58 45.9620.6 57 50.6622.0 51 52.3624.0 0.05
Behavioural score 176 20.0611.9 56 22.5610.3 59 18.0612.6 50 20.9611.7 NS
Functional scores
Functional Assessment Scale 182 32.466.3 59 34.766.5 61 34.867.2 54 36.467.5 0.0005
Independence scale 181 75.6617.2 59 70.6616.3 60 69.0618.6 53 66.5618.9 0.0003
Total Functional Capacity 182 7.863.4 59 6.663.2 62 6.863.3 55 6.263.8 0.004
Cognitive scores
Literacy fluency 1mn 113 18.9611.3 39 14.1611.0 42 16.8612.1 39 13.968.1 0.01
SDMT 108 18.7610.7 33 13.468.9 40 15.5611.6 38 15.769.8 NS
Stroop colour 112 38.6615.8 38 31.2616.6 42 32.4615.6 40 32.1614.0 NS
Stroop word 112 51.7620.7 38 44.7623.0 42 47.3620.5 40 43.5621.2 NS
Stroop interference 112 20.5611.1 37 14.3610.0 42 15.9612.0 40 16.0611.5 0.007
SDMT: Symbol digit modality test, BMI: body mass index.
Mean 6 SD.
doi:10.1371/journal.pone.0085430.t002
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the treatment as well as antidepressant undertaken, there was no
difference in the changes in motor and behavioural symptoms
between the patients on different treatments. The decline in
functional score was less severe with dibenzodiazepines than with
other APRs. Benzamides were associated with more rapid
cognitive decline than the other antipsychotics.
The rate of decline of these patients was similar to that seen in
other cohorts (TFC: 0.8060.00 vs. 0.6360.75 units per year for
129 patients [14], 1.460.1 units per year for 92 patients with
average follow-up of 3.7 years [15], 0.6861.39 units per year for
42 patients with average follow-up of 1.9 years [16]; motor
capacity: 4.4060.20 vs. 4.4267.30 units per year [16]). This
suggests that our results on effectiveness could be generalised to
stages 1 to 3 of the disease. Although our study addressed a rare
disease, the number of patients and the length of the study
provided sufficient statistical power to obtain significant results.
The study is novel in that it provides a comparison of different
APRs used in treating HD. We were also able to follow patients for
much longer than the relatively short follow-up times of clinical
trials (4–12 weeks in clinical trials for antipsychotic drugs [5] vs.
more than two years in our study).
A secondary goal of this study was to compare disease
progression in the four groups of treated patients with that in
non-medicated patients. Because, never-treated patients were less
severely affected, the value of this group for comparisons provided
limited information (even if we use multiple propensity score). A
further sub-analysis was performed with patients who received
APRs after 2006. This was due to possible changes in prescription
Table 3. Pairwise comparisons of effectiveness during the treatment period.
Dibenzodiazepinesseses Risperidone Tetrabenazine
Motor score (n = 305) Risperidone 0.0561.06
Tetrabenazine 22.1561.29 22.2161.53
Benzamides 21.7761.21 21.8261.46 0.3961.64
Behavioural score (n = 305) Risperidone 20.6560.93
Tetrabenazine 21.1061.04 0.5561.26
Benzamides 0.5261.06 1.1761.28 0.6261.36
Functional scores
Functional Assessment Scale (n = 301) Risperidone 20.5560.33
Tetrabenazine 20.0960.38 0.4560.46
Benzamides 20.6160.36 20.0660.44 20.5160.48
Independence scale (n = 297) Risperidone 20.1660.85
Tetrabenazine 21.1060.97 20.9361.18
Benzamides 20.1760.92 0.0061.14 0.9361.23
Total Functional Capacity (n = 301) Risperidone 20.4160.17 * {
Tetrabenazine 20.5460.19 * 20.1360.24
Benzamides 20.3160.19 0.1060.23 0.2360.25
Cognitive scores
Literacy fluency 1 mn (n = 210) Risperidone 0.3460.74
Tetrabenazine 1.1960.74 0.8460.95
Benzamides 20.7960.74 21.1360.95 21.9760.94 *
SDMT (n = 201) Risperidone 0.6760.57
Tetrabenazine 0.0660.55 20.6160.72
Benzamides 21.0260.49 * 21.7060.68 * 21.0860.67
Stroop colour (n = 201) Risperidone 0.2260.93
Tetrabenazine 0.4760.92 0.2461.20
Benzamides 21.9960.85 * 22.2161.15 22.4661.14 *
Stroop word (n = 206) Risperidone 0.4961.38
Tetrabenazine 0.8461.36 0.3561.78
Benzamides 21.8061.27 22.2961.70 22.6361.69
Stroop interference (n = 205) Risperidone 0.0360.73
Tetrabenazine 0.6360.71 0.6060.94
Benzamides 21.4260.66 * 21.4560.90 22.0560.88 *
Adjusted difference (line minus column) in mean change per year 6 standard error.
SDMT: Symbol digit modality test.
*P,0.05.
{ Scores were reversed if necessary (change under risperidone minus the change under dibenzodiazepines = 20.41); the mean evolution of TFC was greater with
dibenzodiazepines than with risperidone.
doi:10.1371/journal.pone.0085430.t003
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habits for tetrabenazine, following the new marketing authorisa-
tion in 2005. The results support the same conclusions as the full
data sample. The mean time lag between first visit and
prescription was 13 months. It is possible that a patient’s health
could deteriorate during this period and that the administration of
APRs could have been started without a visit to a participating
centre. We conducted a sub-analysis of the patients for who this
delay was only six months or less. The findings were consistent
with those for the complete data set (data not shown). Drugs within
one class could have a different effect and side effect profile, more
patients are needed to analyse each drugs separately. Finally, the
side effect profile of APRs depends to a large extent on the dose
prescribed. Unfortunately, medicated doses were not available in
our study.
In our cohort, tetrabenazine and benzamides tended to be given
to patients with a more impaired motor score at the time of first
prescription. This may be because they are the only APRs to have
market authorisation in France for treatment of motor disability
and, in particular, chorea. However, there was no difference in
motor decline between patients treated with tetrabenazine and
those treated with other APRs (0.860.5 units per year). This result
contrasts with previous studies showing an improvement in chorea
under tetrabenazine by a mean of 5.0 units on the UHDRS after
12 weeks [17] and by 4.6 units after 80 weeks in an open-label
continuation study [18]. Tetrabenazine might be less effective
against motor symptom progression in the long term, and this
would explain the discordance between our and previous studies.
Less evidence is available for olanzapine: only one open-label
study has shown improvement of the motor scale [19] whereas in
two other open-label studies, the statistical tests indicated no
significant differences [20,21]. Two trials with tiapride (the most
commonly used benzamide) produced contradictory results and
used reduced movement count rather than the UHDRS score to
assess motor features [22]. To our knowledge, no clinical trials
have assessed risperidone in HD.
Our functional assessments with the TFC scale revealed
differences between APR groups. In a multicentre, double-blind,
controlled trial (TETRA-HD), 84 ambulatory patients with HD
were randomised to receive either tetrabenazine (n = 54) or a
placebo (n = 30) for 12 weeks. Tetrebenazine was found to have a
deleterious effect on functional capacity [17]. A mild improvement
in the disability scale score was observed in case studies with
risperidone [23] and olanzapine [24]. A small-scale trial compar-
ing tiapride treatment to a placebo found no difference in
functional scores [25].
Antipsychotics may act on multiple psychiatric symptoms. The
summary of product characteristics for tetrabenazine states that it
is not advisable to initiate this treatment for patients suffering from
symptoms of depression. Depressed mood, low self-esteem, anxiety
and suicidal ideation as assessed with the UHDRS at baseline did
not differ between treatment groups. This suggests that tetraben-
azine was not only used in patients with less severe depressive
symptoms. Our study shows no difference in behavioural scores
between patients on different APRs. It provides no evidence for a
deleterious effect of tetrabenazine, or a beneficial effect of
dibenzodiazepines, on psychiatric symptoms. In contrast with
our results, two small open-pilot studies showed a significant
improvement in some UHDRS psychiatric sub-scores (depression,
anxiety, irritability and obsessions) after olanzapine treatment and
in the short term [21][20]. There are also case reports of successful
risperidone use in aggressive HD patients [26].
Although APRs are commonly used in Huntington’s disease,
only the TETRA-HD study has reported the effect of tetraben-
azine on cognition. Stroop word-reading scores were worse in the
tetrabenazine than the placebo group [17]. In our study,
tetrabenazine was more effective than benzamides on Stroop
colour, Stroop interference and verbal fluency tests. As observed in
schizophrenia [27], the decline in digit symbol test scores is smaller
with dibenzodiazepines than with benzamides. Thus, the effect of
APRs on cognition should be considered when prescribing an
antipsychotic for patients with HD.
Weight loss is a common feature in Huntington’s disease [28];
the impact of APRs on changes in body mass index over time is
well known. As expected, patients under benzodiazepines or
risperidone did not loss weight. However, these drugs are
associated with weight gain in schizophrenia [29].
In conclusion, we observed similar changes in motor and
behavioural scores. Patients taking dibenzodiazapine presented
fewer declines in functional scores than patients receiving
risperidone and tetrabenazine. Benzamides tended to be associ-
ated with the greatest cognitive decline. These differences may be
explained by differential pharmacological mechanisms. Tetraben-
azine is chemically related to antipsychotic drugs but works as a
dopamine depletor by inhibiting the central vesicular monoamine
transporter [30]. Benzamides are selective for dopaminergic D2
receptors, dibenzodiazepine and risperidone are less selective for
dopaminergic receptors and are antagonists of serotoninergic and
alpha-adrenergic receptors. The findings of this observational
study, which may have been affected by unmeasured or
unaccounted factors, need to be confirmed by further controlled
studies. Consequently, we have now initiated a multicentre
randomised controlled study (Neuro-HD) comparing olanzapine,
tetrabenazine and tiapride. The results are expected in three years.
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